Co-Authors
This is a "connection" page, showing publications co-authored by SATTVA S NEELAPU and FULIANG CHU.
Connection Strength
3.158
-
Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas. J Immunother Cancer. 2023 11 24; 11(11).
Score: 0.926
-
CXCR5+CD8+ T cells are a distinct functional subset with an antitumor activity. Leukemia. 2019 11; 33(11):2640-2653.
Score: 0.674
-
Anti-PD-1 antibodies for the treatment of B-cell lymphoma: Importance of PD-1+ T-cell subsets. Oncoimmunology. 2014 Jan 01; 3(1):e28101.
Score: 0.466
-
Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma. Blood Adv. 2022 02 22; 6(4):1143-1151.
Score: 0.205
-
CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. Blood. 2021 09 23; 138(12):1081-1085.
Score: 0.199
-
Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma. Int J Cancer. 2014 Dec 15; 135(12):2834-46.
Score: 0.120
-
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014 Jan; 15(1):69-77.
Score: 0.116
-
Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment. J Immunol. 2013 Jun 15; 190(12):6681-93.
Score: 0.112
-
TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas. Blood. 2012 Aug 23; 120(8):1613-23.
Score: 0.104
-
Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment. Breast Cancer Res. 2023 06 06; 25(1):62.
Score: 0.056
-
Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment. Res Sq. 2023 Feb 14.
Score: 0.055
-
IL-15 enhances the antitumor effect of human antigen-specific CD8+ T cells by cellular senescence delay. Oncoimmunology. 2016; 5(12):e1237327.
Score: 0.035
-
Bypassing STAT3-mediated inhibition of the transcriptional regulator ID2 improves the antitumor efficacy of dendritic cells. Sci Signal. 2016 09 27; 9(447):ra94.
Score: 0.035
-
Transcription factor achaete-scute homologue 2 initiates follicular T-helper-cell development. Nature. 2014 Mar 27; 507(7493):513-8.
Score: 0.029
-
Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions. Nat Med. 2011 Jul 24; 17(8):983-8.
Score: 0.025